Stock Price Quote

MOREPEN LABORATORIES LTD.

NSE : MOREPENLABBSE : 500288ISIN CODE : INE083A01026Industry : Pharmaceuticals & DrugsHouse : Morepen
BSE55.903.83 (+7.36 %)
PREV CLOSE ( ) 52.07
OPEN PRICE ( ) 52.12
BID PRICE (QTY) 55.85 (1051)
OFFER PRICE (QTY) 55.91 (851)
VOLUME 4435235
TODAY'S LOW / HIGH ( )51.85 56.25
52 WK LOW / HIGH ( )27.4 56.35
NSE56.204.15 (+7.97 %)
PREV CLOSE( ) 52.05
OPEN PRICE ( ) 52.30
BID PRICE (QTY) 56.20 (200)
OFFER PRICE (QTY) 56.21 (1683)
VOLUME 26926471
TODAY'S LOW / HIGH( ) 51.87 56.25
52 WK LOW / HIGH ( )27.4 56.4
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1984
Management Info
Sushil Suri - Chairman Sushil Suri - Managing Director
Registered Office

Address Morepen Village, Malkumajra,Nalagarh Road,Near Baddi,
Solan Dist,
Himachal Pradesh-173205

Phone 01795-246401 / 02 / 03 / 244590

Email plants@morepen.com

Website www.morepen.com

Registrars Details
MAS Services Ltd
T-34 , 2nd Floor,Okhla Industrial Area,Phase - II,New Delhi
Listing : BSE, NSE

NEWS

02May Change In The Date Of Appointment - S
Please find enclosed letter w.r.t., change in date of appointment of Mr...
23Apr Morepen Laboratories informs about PCS
Morepen Laboratories has informed that it enclosed certificate under Reg..
18Mar Morepen Laboratories informs about out
Morepen Laboratories has informed that pursuant to Regulation 30 of SEBI..
31Jan Morepen Laboratories informs about out
Morepen Laboratories has informed that the Board of Directors of the com..
16Dec Morepen Laboratories informs about los
Morepen Laboratories has informed that it attached letter comprising det..

Financials

in Millions
QTR Mar 24 ANNUAL 24
Net Profit399.591109.35
Gross Profit 527.06 1489.75
Operating Profit 601.221743.84
Net Sales 392615375.94

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Sanofi India (BSE)
peergroup  6838.70 (5.00%)
M.Cap ( in Cr)15749.95
Astrazeneca Pharma I (BSE)
peergroup  6477.65 (1.99%)
M.Cap ( in Cr)16262.50
NGL Fine-Chem (BSE)
peergroup  2388.80 (2.30%)
M.Cap ( in Cr)1475.81
Strides Pharma Scien (BSE)
peergroup  979.05 (3.92%)
M.Cap ( in Cr)9082.29
Procter&Gamble Healt (BSE)
peergroup  5025.00 (0.74%)
M.Cap ( in Cr)8296.37

Shareholding Pattern

NON-INSTITUTION 57.77%
PROMOTERS 38.22%
FI/BANKS/INSURANCE 2.15%
GOVERNMENT 0.01%
MUTUAL FUNDS/UTI 0%
FII 0%

About Morepen Laboratories Ltd.

Morepen Laboratories Ltd. was incorporated in the year 1984. Its today's share price is 55.9. Its current market capitalisation stands at Rs 2801.72 Cr. In the latest quarter, company has reported Gross Sales of Rs. 13388.83 Cr and Total Income of Rs.13446.42 Cr. The company's management includes Vipul Kumar Srivastava, Savita, Praveen Kumar Dutt, Sukhcharan Singh, Bhupender Raj Wadhwa, Manoj Joshi, Sanjay Suri, Sushil Suri, Sushil Suri.

It is listed on the BSE with a BSE Code of 500288 , NSE with an NSE Symbol of MOREPENLAB and ISIN of INE083A01026. It's Registered office is at Morepen Village, Malkumajra,Nalagarh Road,Near BaddiSolan Dist-173205, Himachal Pradesh. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are M Kamal Mahajan & Co, M Kamal Mahajan & Co LLP, Satinder Goyal & Co, SP Babuta & Associates

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.